1. Scrip
  2. >>Business

Allo CAR-T Is Still On The Shelf As Precision Moves On

Company Pivots To In Vivo Editing

 
• By Andrew McConaghie

Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.

Precision Biosciences

Precision BioSciences, which had hoped to be the first company to bring an allogeneic CAR-T to market, has announced its exit from the field with the sale of its lead asset, azercabtagene zapreleucel (azer-cel).

It is walking away from the allo CAR-T field altogether, pivoting to focus entirely on in vivo gene editing therapies,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.